Xintela publishes Phase I/IIa data showing XSTEM improves pain, function in knee osteoarthritis study

Reuters2026/08/11 06:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xintela published peer-reviewed Phase I/IIa results for XSTEM in knee osteoarthritis in the journal Cartilage; results were previously presented in September 2025.
The study showed the treatment was well tolerated, with no serious treatment-related safety issues reported.
Patients reported reduced knee pain and improved joint function, supporting a potential disease-modifying effect.
The highest dose showed sustained improvements in cartilage and bone tissue quality for up to two years, with signs of slowing cartilage breakdown.
Publication increases visibility of the dataset for potential partners, strengthening the investment case for further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xintela AB published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xintela publishes Phase I/IIa data showing XSTEM improves pain, function in knee osteoarthritis study

You may also like

Crypto prices